TABLE 3.
Neutralization properties of SHIV stocks in TZM-bl assaysa
| Specificity | Antibody | SHIV stock (neutralization sensitivity) |
|||||
|---|---|---|---|---|---|---|---|
| 327c | 327cRM | 405c | 459c | 590c | 823cD6 | ||
| CD4 | sCD4 | >50 | 0.07 | >50 | 48.66 | >50 | >50 |
| CD4bs | b12 | >50 | >50 | >50 | >50 | >50 | >50 |
| 3BNC117 | 1.82 | 2.49 | 4.94 | 5.97 | 0.99 | 5.37 | |
| VRC01 | 2.23 | 1 | 13.31 | 11.95 | 2.96 | 1.99 | |
| 45-46W | 0.22 | 0.085 | 1.83 | 3.12 | 0.358 | 0.751 | |
| V3/CD4i | 3BNC176 | >50 | >50 | >50 | >50 | >50 | >50 |
| gp120 (V3/V4) | 2G12 | >50 | >50 | >50 | >50 | >50 | >50 |
| V1/V2 glycan | PG9 | 30.2 | >50 | 17.41 | >50 | 0.39 | 2.12 |
| PG16 | 15.38 | >50 | 2.05 | 6.7 | <0.023 | 0.089 | |
| V3 glycan | PGT128 | >50 | >50 | 45.94 | 0.65 | 0.18 | 0.12 |
| PGT121 | 1.38 | 0.292 | <0.023 | 0.173 | <0.023 | 0.05 | |
| PGT126 | >50 | >50 | >50 | 42.9 | 0.153 | 0.528 | |
| 10-1074 | 0.056 | <0.023 | <0.023 | 0.427 | 0.032 | 0.398 | |
| gp41/CD4bs | 8ANC195 | >50 | >50 | 18.13 | >50 | 44.05 | 0.461 |
| gp41 (MPER) | 2F5 | >50 | >50 | >50 | >50 | >50 | >50 |
| 4E10 | >50 | 24.01 | 18.25 | >50 | >50 | >50 | |
| 10E8 | 23.66 | 3.61 | 0.983 | 16.03 | >50 | >50 | |
| Polyclonal | HIVIG-B | >2,500 | 603.01 | >2,500 | >2,500 | >2,500 | >2,500 |
| HIVIG-C | 593.8 | 85.66 | 361.51 | 354.42 | 140.42 | 361.64 | |
| HIVIG-C2 | 2,147.37 | 97.07 | 392.16 | >2,500 | 848.05 | >2,500 | |
| HIVIG-C8 | 1,246.4 | 99.68 | 971.81 | 1,301.66 | 459.49 | 1,949.13 | |
| HIVIG-C44 | 893.5 | 175.36 | >2,500 | 1,427.02 | 565.25 | 1,490.73 | |
| HIVIG-C62 | 1,232.82 | 368.21 | 1,101.63 | >2,500 | 1,486.69 | >2,500 | |
| HIVIG-C72 | >2,500 | 127.36 | >2,500 | >2,500 | >2,500 | >2,500 | |
| HIVIG-C74 | >2,500 | 84.79 | 2,385.27 | >2,500 | 855.51 | >2,500 | |
a
CD4bs, CD4 binding site; CD4i, CD4 induced site; HIVIG, purified immunoglobulin obtained from clade C HIV+ plasma samples.